Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid

Annals of Pharmacotherapy

Volumn 31, Issue 10, 1997, Pages 1153-1156

  Morikawa, Norifumi ^a   Mori, Teruaki ^a   Abe, Tatsuya ^a   Ghoda, Makoto ^a   Takeyama, Masaharu ^a   Hori, Shigeaki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Cerebrospinal fluid; Methotrexate

Indexed keywords

METHOTREXATE; PEPLEOMYCIN; VINDESINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; GLIOBLASTOMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030964645     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101007     Document Type: Article

References (15)

1. Mahaley MS, Hipp S, Dropcho E, Bertsch L, Cush S, Tirey T, et al. Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 1989;70:371-8.
2. Nakagawa H, Fujita T, Hubo S, Turuzono K, Yamada M, Tokiyoshi K, et al. Selective intra-arterial chemotherapy with a combination of etoposide and cisplatin for malignant glioma: preliminary report. Surg Neurol 1994;41:19-27.
3. Stewart DJ, Wallace S, Feun L, Luna M, Bonura J, Capriole R, et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 1982;42:2059-62.
4. Madajewicz S, Chowhan N, Iliya A, Roque X, Beaton R, Davis R, et al. Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors. Cancer 1991;67:2844-9.
5. Gumerlock MK, Belshe BD, Madsen R, Watts C. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncol 1992; 12:33-46.
6. Neuwelt EA, Barnett P, McCormick C, Frenkel EP, Minna JD. Osmotic blood-brain barrier modification: monoclonal antibody, albumin and methotrexate delivery to CSF and brain. Neurosurgery 1985;17:419-23.
7. Cosolo WC, Christophidis N. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats. Cancer Res 1987;47:6225-8.
8. Cosolo WC, Martinello P, Louis WJ, Christophidis N. Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. Am J Physiol 1989;256:443-7.
9. Williams JA, Goldstein SR, Crossen JR, D'Agostino A, Dahlborg A, Neuwelt EA. Preirradiation osmotic blood-brain barrier disruption plus combination chemotherapy in gliomas: quantitation of tumor response to assess chemosensitivity. Adv Exp Med Biol 1993;331:273-84.
10. Pesce MA, Bodourian SH. Evaluation of a fluorescence polarization immunoassay procedure for quantitation of methotrexate. Ther Drug Monit 1986;8:115-21.
11. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 1981;4:879-85.
12. Neuwelt EA, Howieson J, Frankel EP, Specht D, Weigel R, Buchan CG, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986;19:573-82.
13. Hayashi A, Kyuma Y. Intra-arterial infusion of high dose methotrexate therapy in recurrent glioma. Jpn J Cancer Chemother 1990;17:1461-6.
14. Shapiro WR, Young DF, Mehta BM. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975;293:161-6.
15. Miller KT, Wilkinson DS. Pharmacokinetics of methotrexate in the cerebrospinal fluid after intracerebroventricular administration in patients with meningeal carcinomatosis and altered cerebrospinal fluid flow dynamics. Ther Drug Monit 1989;11:231-7.